Related content

A phase I study of neoadjuvant chemotherapy with gemcitabine plus oral S-1 for resectable pancreatic cancer

By                                          

Molecular and Clinical Oncology, Vol. 1, Iss. 4, 2013-01 ,pp. : 768-772

Spandidos Publications

Access to resources Recommend Favorite

Phase II study of ifosfamide, etoposide, and oxaliplatin (IFETOx) chemotherapy for relapsed or refractory non-Hodgkin’s lymphoma

By Kim Seon-Kyeong   Song Moo-Kon   Chung Joo   Shin Ho-Jin  

International Journal of Hematology, Vol. 98, Iss. 5, 2013-11 ,pp. : 543-548

Springer Publishing Company

Access to resources Recommend Favorite

Feasibility of adjuvant chemotherapy with S-1 consisting of a 4-week administration and a two-week rest period in patients with completely resected non-small cell lung cancer

By Okumura  

Molecular and Clinical Oncology, Vol. 1, Iss. 1, 2013-01 ,pp. : 124-130

Spandidos Publications

Access to resources Recommend Favorite

Phase II study on the combination of irinotecan plus cisplatin as a secondline therapy in patients with advanced or recurrent gastric cancer

By                    

Molecular and Clinical Oncology, Vol. 1, Iss. 4, 2013-01 ,pp. : 749-752

Spandidos Publications

Access to resources Recommend Favorite

Serum iron levels as a new biomarker in chemotherapy with leucovorin and fluorouracil plus oxaliplatin or leucovorin and fluorouracil plus irinotecan, with or without molecularly-targeted drugs

By                            

Molecular and Clinical Oncology, Vol. 1, Iss. 5, 2013-01 ,pp. : 805-810

Spandidos Publications

Access to resources Recommend Favorite